Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07985631 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: single ascending dose | EXPERIMENTAL | Dose A (3 active: 2 placebo) |
| Cohort 2: single ascending dose | EXPERIMENTAL | Dose B (3 active: 2 placebo) |
| Cohort 3: single ascending dose | EXPERIMENTAL | Dose C (6 active: 2 placebo) |
| Cohort 4: single ascending dose | EXPERIMENTAL | Dose D (6 active: 2 placebo) |
| Cohort 5: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 6: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 7: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 8: single dose | EXPERIMENTAL | Optional Japanese Cohort dose to be determined (4 active: 1 placebo) |
| Cohort 9: single dose | EXPERIMENTAL | Optional Chinese Cohort dose to be determined (4 active: 1 placebo) |
| Cohort 10: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 11 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 12 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 13 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Name | Type | Description |
|---|---|---|
| PF-07985631 | DRUG | Experimental Pfizer compound which will be SC or IV |
| Placebo | DRUG | Placebo which will be SC or IV |
Inclusion: 1. Between 18 and 45 years of age who are overtly healthy. 2. Japanese/Chinese and multiple dose cohorts only: Adult participants 18 to 55 years of age who are overtly healthy may be eligible at the discretion of PI. 3. Japanese/Chinese cohorts only: Participants must have 4 biological J...
PF-07985631 is an investigational small molecule medicine being developed by Pfizer. It is currently in Phase 1 clinical development, where it is being studied in healthy adult volunteers to learn how different amounts of the study medicine are tolerated and how it acts in the body.
PF-07985631 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating this investigational small molecule medicine.
PF-07985631 is in Phase 1 clinical development. It is an investigational medicine and has not been approved by the FDA. The Phase 1 program is designed to assess tolerability and how the study medicine behaves in the body of healthy adult participants.
PF-07985631 is being studied in one active clinical trial, NCT06994897, titled a study to learn how different amounts of the study medicine called PF-07985631 are tolerated and act in the body of healthy adults. The trial is currently recruiting and is expected to enroll 92 participants in Belgium.
The Phase 1 trial of PF-07985631, NCT06994897, is a randomized, double-blind, controlled study. It is enrolling 92 healthy adult volunteers of all sexes, aged 18 years and older, at sites in Belgium. The study is currently recruiting participants.